Combination therapy • Enrollment open • Trial initiation date • PD(L)-1 companion diagnostic • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
VENTANA PD-L1 (SP263) Assay
|
Keytruda (pembrolizumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • VB10.16